Trial Profile
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, to Expedite Engraftment and Improve Transplant Outcome
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Omidubicel (Primary)
- Indications Aplastic anaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 11 May 2023 Planned primary completion date changed from 28 Apr 2023 to 28 Apr 2024.
- 21 Jan 2022 Planned End Date changed from 31 Dec 2023 to 1 Mar 2028.
- 21 Jan 2022 Planned primary completion date changed from 4 Apr 2022 to 28 Apr 2023.